

A Letter from the Founder

Hello CCTC Members,

Thank you for your ongoing support. By providing up-to-date and consolidated information about ongoing clinical trials, we hope to further benefit patients and ultimately increase trial enrollment. In turn, this may allow for more trials to be considered in Ontario.

Please let us know if you have any concerns or suggestions for website improvement. Be sure to follow us on Twitter [@COMET_Trials](https://twitter.com/COMET_Trials) for the latest updates regarding open trials.

Sincerely,
Dr. Christine Brezden-Masley

A Letter from the Project Manager

Hello everyone,

If there are any trials that have opened or closed to accrual at your site please feel free to contact me at cometrials@smh.ca and I would be happy to update the website on your behalf.

As always, please feel free to share this newsletter with any colleagues who may be interested. We are always happy to have new members join the network and promote the trials they are involved with.

Kind Regards,
Alexandra Moskalewicz

ARTICLE RECOMMENDATION

Health disparities and clinical trial recruitment: Is there a duty to tweet?

Caplan A, Friesen P.

DOI:10.1371/journal.pbio.2002040. PLoS Biol. Published March 1, 2017.

ABSTRACT:

While it is known that the homogeneity of clinical trial participants often threatens the goal of attaining generalizable knowledge, researchers often cite issues with recruitment, including a lack of interest from participants, shortages of resources, or difficulty accessing particular populations, to explain the lack of diversity within sampling. It is proposed that social media might provide an opportunity to overcome these obstacles through affordable, targeted recruitment advertisements or messages. Recruiters are warned, however, to be cautious using these means, since risks related to privacy and transparency can take on a new hue.

TRIALS SNAPSHOT

Trial Type	Imaging	Observational	Prevention	Radiation Therapy	Supportive Care	Surgical Therapy	Systemic Therapy	Therapeutic	Total
Any Malignancy		1		2			7	1	11
Breast	2	3		3	3	1	9		21
CNS				1			1	1	3
GI		1	1	3			13	1	19
GU	1	1		5		1	17	1	26
Gyne						1	7	2	10
Head&Neck				2	1	1	3	1	8
Heme		2	1				14	1	18
Lung				9			4		13
Melanoma							6		6
Skin							1	1	2
Sarcoma		1							1
NET							1		1
Total	3	9	2	25	4	4	83	9	139



TRIALS OF THE MONTH

Type	Acronym	Study Title	Description	Site(s)
Breast	VIOLETTE	A Phase II, Open Label, Randomised, Multi-centre Study to Assess the Safety and Efficacy of Agents Targeting DNA Damage Repair in Combination With Olaparib Versus Olaparib Monotherapy in the Treatment of Metastatic Triple Negative Breast Cancer Patients Stratified by Alterations in Homologous Recombinant Repair (HRR)-Related Genes	<ul style="list-style-type: none"> Metastatic Triple Breast Cancer Systemic Therapy 	Odette Cancer Centre
GU	AL-ACC-01 / ACCURACY	A Phase 2, Open-Label, Single-Arm, Multi-Center Study Of AL101 (BMS-906024) In Patients With Adenoid Cystic Carcinoma (ACC) Bearing Activating Notch Mutations	<ul style="list-style-type: none"> Recurrent or Metastatic Adenoid Cystic Carcinoma Systemic Therapy 	London Health Sciences Centre
GI	KEYNOTE-859	A Phase 3, Randomized, Double-blind Clinical Study of Pembrolizumab Plus Chemotherapy vs. Placebo Plus Chemotherapy as First-line Treatment in Participants With HER2 Negative, Previously Untreated, Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma	<ul style="list-style-type: none"> Gastric or GE Junction Adenocarcinoma Systemic Therapy 	Odette Cancer Centre
Heme	PEV 3001	A Phase 3, Randomized, Controlled, Open-label, Clinical Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Low-Blast Acute Myelogenous Leukemia	<ul style="list-style-type: none"> 1st Line Systemic Therapy 	Odette Cancer Centre
Any	NIMBLE	A Phase II Open Label, Randomized Non-Comparative Trial of Nivolumab Alone or in Combination With Ipilimumab for the Treatment of Patients With Advanced Hypermutated Solid Tumors Detected by a Blood Based Assay	<ul style="list-style-type: none"> Metastatic or Unresectable Solid Tumors Systemic Therapy 	Juravinski Cancer Centre
Sarcoma	RESAR	REtroperitoneal SArcoma Registry (RESAR): Prospective Collection of Primary Retroperitoneal Sarcoma Patient's Data, Radiological and Pathological Material for the Trans-Atlantic Retroperitoneal Sarcoma Working Group	<ul style="list-style-type: none"> Retroperitoneal Sarcoma Observational Registry 	The Ottawa Hospital
Melanoma	LEAP 4	Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) for Advanced Melanoma in Anti-Programmed Death-1/Programmed Death-Ligand 1 (PD-1/L1)-Exposed Participants	<ul style="list-style-type: none"> Stage III or IV Systemic Therapy 	Odette Cancer Centre






MEMBERSHIP UPDATES

139 accruing trials

288 members

30 institutions



INSTITUTIONS

Institution	Location	Trials	Members
Cambridge Memorial Hospital	Cambridge	3	4
Grand River Hospital	Kitchener	-	7
Humber River Regional Hospital	Toronto	1	5
Kingston General Hospital	Kingston	26	3
Juravinski Cancer Centre	Hamilton	1	7
Lakeridge Health Corporation	Oshawa	-	20
London Health Sciences Centre	London	83	11
Mackenzie Health Hospital	Richmond Hill	-	6
Markham Stouffville Hospital	Markham	-	4
Mount Sinai Hospital	Toronto	1	2
North York General Hospital	Toronto	2	14
Odette Cancer Centre/Sunnybrook	Toronto	50	65
Ontario Institute for Cancer Research	Toronto	-	4
Ontario Hospital	Toronto	-	1
Ottawa Hospital	Ottawa	1	3
Princess Margaret Cancer Centre	Toronto	1	25
Quinte Health Care	Belleville	-	1
Rouge Valley Health System	Ajax	-	3
Royal Victoria Regional Health Centre	Barrie	10	23
Scarborough General Hospital	Toronto	-	3
Southlake Regional Health Centre	Newmarket	7	21
St. Joseph's Healthcare	Hamilton	-	4
St. Joseph's Health Centre	Toronto	-	3
St. Michael's Hospital	Toronto	7	14
Sudbury Regional Hospital	Sudbury	-	1
Thunder Bay Regional	Thunder Bay	-	2
Toronto General Hospital	Toronto	1	3
Trillium Health Partners	Mississauga	3	18
William Osler Health Systems	Brampton	-	3
Windsor Regional Hospital	Windsor	-	2

ACKNOWLEDGEMENTS

The CCTC has been funded by unrestricted educational grants from the following supporters:



CONTACT US

Do you have any questions, feedback, suggestions? Please do not hesitate to contact us.

30 Bond Street
Toronto, ON Canada
M5B 1W8
cometrials@smh.ca